Azitra, Inc. (NYSEAMERICAN:AZTR) Short Interest Update

Azitra, Inc. (NYSEAMERICAN:AZTR) was the target of a significant decline in short interest in August. As of August 14th, there was short interest totaling 20,858 shares, a decline of 86.5% from the July 30th total of 154,671 shares. Based on an average trading volume of 2,242,858 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the company’s stock are short sold.

Azitra Price Performance

Shares of NYSEAMERICAN AZTR traded down $0.01 on Friday, reaching $0.18. 871,660 shares of the company’s stock traded hands, compared to its average volume of 9,582,451. The business’s 50 day simple moving average is $0.15 and its two-hundred day simple moving average is $0.19. Azitra has a 12 month low of $0.10 and a 12 month high of $1.09.

Azitra (NYSEAMERICAN:AZTR) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.05). Analysts expect that Azitra will post -0.25 EPS for the current fiscal year.

Azitra Company Profile

Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.

The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.